Florence M. Hofman

University of Southern California — United States

Medicine · Health Sciences

64h-index15.1kcitations264works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Glioma Diagnosis and Treatment(79), Immunotherapy and Immune Responses(20), Endoplasmic Reticulum Stress and Disease(20), Neuroinflammation and Neurodegeneration Mechanisms(19), Brain Metastases and Treatment(18)

Publications262 total

Inhibition of autophagy and induction of glioblastoma cell death by NEO214, a perillyl alcohol-rolipram conjugate
Autophagy·2023· 31 citedOpen Access
Data Supplement from NEO212, Temozolomide Conjugated to Perillyl Alcohol, Is a Novel Drug for Effective Treatment of a Broad Range of Temozolomide-Resistant Gliomas
2023Open Access
Data from NEO212 Inhibits Migration and Invasion of Glioma Stem Cells
2023Open Access
Supplementary Figure 3 from Perillyl Alcohol for the Treatment of Temozolomide-Resistant Gliomas
2023Open Access
Supplementary Figure 1 from Perillyl Alcohol for the Treatment of Temozolomide-Resistant Gliomas
2023Open Access
Figure S5 from The Rolipram–Perillyl Alcohol Conjugate (NEO214) Is A Mediator of Cell Death through the Death Receptor Pathway
2023Open Access
Data from The Rolipram–Perillyl Alcohol Conjugate (NEO214) Is A Mediator of Cell Death through the Death Receptor Pathway
2023Open Access
Data Supplement from NEO212, Temozolomide Conjugated to Perillyl Alcohol, Is a Novel Drug for Effective Treatment of a Broad Range of Temozolomide-Resistant Gliomas
2023Open Access
Figure S5 from The Rolipram–Perillyl Alcohol Conjugate (NEO214) Is A Mediator of Cell Death through the Death Receptor Pathway
2023Open Access
Supplementary Figure 2 from Perillyl Alcohol for the Treatment of Temozolomide-Resistant Gliomas
2023Open Access
Supplementary Figures 1-4 from NEO212 Inhibits Migration and Invasion of Glioma Stem Cells
2023Open Access
Data from NEO212, Temozolomide Conjugated to Perillyl Alcohol, Is a Novel Drug for Effective Treatment of a Broad Range of Temozolomide-Resistant Gliomas
2023Open Access
Supplementary Figure 1 from Perillyl Alcohol for the Treatment of Temozolomide-Resistant Gliomas
2023Open Access
Data Supplement from NEO212, Temozolomide Conjugated to Perillyl Alcohol, Is a Novel Drug for Effective Treatment of a Broad Range of Temozolomide-Resistant Gliomas
2023Open Access
Supplementary Figures 1-4 from NEO212 Inhibits Migration and Invasion of Glioma Stem Cells
2023Open Access
Supplementary Figure Legends from A Novel Temozolomide–Perillyl Alcohol Conjugate Exhibits Superior Activity against Breast Cancer Cells <i>In Vitro</i> and Intracranial Triple-Negative Tumor Growth <i>In Vivo</i>
2023Open Access
Data Supplement from NEO212, Temozolomide Conjugated to Perillyl Alcohol, Is a Novel Drug for Effective Treatment of a Broad Range of Temozolomide-Resistant Gliomas
2023Open Access
Figure S4 from The Rolipram–Perillyl Alcohol Conjugate (NEO214) Is A Mediator of Cell Death through the Death Receptor Pathway
2023Open Access
Figure S1 from The Rolipram–Perillyl Alcohol Conjugate (NEO214) Is A Mediator of Cell Death through the Death Receptor Pathway
2023Open Access
Supplementary Figure 3 from Perillyl Alcohol for the Treatment of Temozolomide-Resistant Gliomas
2023Open Access
page 1 of 14Next →

Frequent Co-authors

Thomas C. Chen(15), Axel H. Schönthal(12), David R. Hinton(9), Stan G. Louie(7), Berislav V. Zloković(6), Nicos A. Petasis(6), Encouse B. Golden(5), J E Merrill(4), Amy S. Lee(4), Raphael Zidovetzki(4), Niyati Jhaveri(4), Weijun Wang(4), Peter Pyrko(3), Dezheng Dong(3), Jenilyn J. Virrey(3), Ligaya Pen(3), Susan Groshen(3), Hee‐Yeon Cho(3), Roel C. van der Veen(3), Clive R. Taylor(3)